News

The phase I trial is a dose escalating trial in which volunteers will receive three monthly intramuscular doses of vaccine. The trial is designed to confirm that the

Synthon will co-promote Lithobid through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists across the US. Financial terms of the agreement were not

The trial in India is part of a multi-country phase I clinical development program for tgAAC09, an investigational recombinant adeno-associated viral vector (rAAV)-based HIV/AIDS vaccine candidate, that is

Eloxatin (oxaliplatin) injection is a clear, preservative-free solution available in 50mg and 100mg doses. Eloxatin injection offers additional benefit and convenience as it involves fewer steps in the

Under the agreement, St Louis, Missouri-based Tripos will identify and optimize backup series for one of BioTie’s key drug discovery programs. Tripos will then rapidly create compound libraries

Atugen will contribute its target discovery and in-vivo screening know-how while drug design, medicinal chemistry and in-vitro screening expertise will be provided by Asinex. The novel kinase target

If successfully developed, the product would address the multi-billion dollar market opportunity for the prevention and treatment of venous thrombosis and for the prevention and treatment of thromboembolic

The merger will integrate Syrrx’s technologies and R&D pipeline into Takeda and establish a discovery research presence for Takeda in the US. This relationship is expected to help

RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke. There are currently no drugs on